Truvada (TDF) Lawsuit Overview

What Is the Truvada Lawsuit?

Thousands of HIV patients are filing lawsuits against Gilead Sciences alleging that its medications containing tenofovir disoproxil fumarate (TDF) caused severe kidney damage and bone density loss. The lawsuits claim Gilead delayed releasing a safer alternative — tenofovir alafenamide (TAF) — to maximize TDF profits.

Which Drugs Are Involved?

The lawsuits target HIV medications containing TDF:

• Truvada (TDF + emtricitabine)
• Viread (TDF alone)
• Atripla (TDF + emtricitabine + efavirenz)
• Complera (TDF + emtricitabine + rilpivirine)
• Stribild (TDF + emtricitabine + elvitegravir + cobicistat)

These medications are used to treat HIV and prevent its transmission (PrEP).

What Are the Allegations?

The core of the lawsuits is that Gilead developed a safer drug (TAF) but delayed its release to maximize profits from TDF:

• TAF was developed in the early 2000s — much safer for kidneys and bones
• Gilead allegedly shelved TAF to extend TDF patent profits
• TAF wasn't approved until 2015 with newer combination drugs (Genvoya, Descovy, Odefsey)
• By that time, thousands of patients had suffered from TDF side effects
• Patients had no choice — TDF was the only option for years

What Injuries Are Linked to TDF?

Common TDF-related injuries include:

Kidney Damage

• Chronic kidney disease
• Acute kidney injury
• Fanconi syndrome — A serious kidney tubule disorder
• Renal tubular dysfunction
• Kidney failure
• Need for dialysis
• Need for kidney transplant

Bone Damage

• Osteoporosis — Severe bone density loss
• Osteopenia — Decreased bone mass
• Bone fractures — Often from minor injuries
• Hip fractures
• Spinal compression fractures
• Tooth loss

Other Conditions

• Lactic acidosis
• Hepatic steatosis (fatty liver)
• Pancreatitis

The Science

Research has consistently shown that TDF causes more kidney and bone damage than TAF:

• TDF requires high doses to be effective
• TAF allows lower doses with similar efficacy
• Lower doses mean less kidney exposure to potential toxicity
• Bone density loss is significantly greater with TDF
• Long-term TDF use is associated with cumulative damage

What Are Plaintiffs Alleging?

The lawsuits allege that Gilead Sciences:

• Knew about TDF's serious side effects
• Developed TAF as a safer alternative but delayed its release
• Manipulated the drug approval timeline to maximize TDF profits
• Failed to warn patients about the severity of side effects
• Profited at the expense of HIV patients' health
• Continued aggressive marketing of TDF even after TAF was available

Current Status of the Litigation

The Truvada/TDF litigation is consolidated in:

• JCCP 5043 (California state court) — Primary venue
• Federal cases in various jurisdictions
• Thousands of plaintiffs have joined the litigation
• Bellwether trials have been scheduled and held
• No global settlement has been reached

Why You Should Act Now

If you took TDF-based HIV medications and developed kidney or bone problems:

• Statutes of limitations vary by state
• Medical records documenting your TDF use are essential
• Lab results showing kidney function or bone density are critical
• Cases continue to be accepted

A free case review costs nothing. If you experienced kidney or bone problems from HIV medications, you may be entitled to compensation.